Dr. Tam on Results of the CAPTIVATE Trial in CLL
Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).
Related Articles
Shortened Trastuzumab Administration Does Not Improve DFS in ERBB2+ Breast Cancer
Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.
Charlson Comorbidities Associated With Lower Likelihood of CR in Epithelial Ovarian Cancer
Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.
Dual Checkpoint Blockade Usurps PD-1 Monotherapy as Gold Standard in Unresectable Melanoma
Ankit Mangla, MD, expands on key survival data from the phase 2/3 RELATIVITY-047 trial in previously untreated, unresectable, or metastatic melanoma.
Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer
Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.
NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma
An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.
FDA Grants Priority Review to Mirdametinib for NF1-Associated Plexiform Neurofibromas
Priority review was granted to the NDA seeking approval of mirdametinib in patients with neurofibromatosis type 1–associated plexiform neurofibromas.
IBI363 Receives FDA Fast Track Designation for Advanced/Metastatic Melanoma
The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma
The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.
Clinical Scenario I: 68-yr Old Man with Early Relapse MM
Key opinion leaders present a clinical patient scenario involving a 68-year-old male patient presenting with early relapse multiple myeloma.
Final Thoughts on EHA 2024 Data for Lower-Risk MDS
Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.